Clicky

Pluri Inc.(PLUR)

Description: Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.


Keywords: Biotechnology Life Sciences Surgery Radiation Stem Cell Cell Therapy Transplantation Transplantation Medicine Covid 19 Inflammatory Acute Respiratory Distress Syndrome Cell Therapy Products Host Disease Graft Versus Host Disease Surgical Oncology Acute Radiation Syndrome Muscle Injuries Plx Plx Pad Treatment Of Acute Radiation Syndrome Treatment Of Acute Respiratory Distress Syndrome

Home Page: www.pluri-biotech.com

PLUR Technical Analysis

Building No. 5
Haifa, 3508409
Israel
Phone: 972 74 710 8600


Officers

Name Title
Mr. Yaacov Yanay Pres, CEO & Director
Ms. Chen Franco-Yehuda CFO, Treasurer & Sec.
Mr. Lior Raviv Chief Technology Officer
Ms. Efrat Livne-Hadass VP of HR
Dr. Nitsan Halevy M.D. Chief Medical Officer
Mr. Nimrod Bar Zvi Chief Commercial Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.2412
Price-to-Sales TTM: 102.2445
IPO Date: 2003-06-30
Fiscal Year End: June
Full Time Employees: 154
Back to stocks